Bruker’s Energy & Superconductors (BEST) division announced that it has secured two multi‑year supply agreements totaling approximately $500 million in expected future revenue. The contracts, which extend up to seven years for one of the agreements, are expansions of existing framework agreements and will deliver superconducting wire to Bruker’s U.S. and U.K. production sites.
The $500 million commitment represents a substantial addition to BEST’s revenue pipeline. In FY 2024 the division generated $283 million, and the new agreements will provide a steady stream of revenue over the coming years, helping to offset recent quarterly declines of 4.1 % in Q4 2024 and 18.9 % in Q1 2025. The long‑term nature of the contracts also improves cash‑flow predictability for the division.
Bruker is the world’s largest manufacturer of superconducting wire and has positioned itself at the forefront of helium‑free MRI magnet technology. The new agreements will support the development of next‑generation MRI systems that eliminate the need for liquid helium, a major cost and supply‑chain advantage. In addition to MRI, BEST’s superconductors are used in proton therapy, NMR, EPR spectroscopy, magnetic‑confinement fusion, superconducting wind turbines, and high‑energy physics experiments, underscoring the breadth of the technology’s applications.
The agreements come at a time when Bruker’s overall revenue guidance for FY 2025 is $3.47 billion to $3.54 billion, up from $3.37 billion in FY 2024. The addition of $500 million in future BEST revenue strengthens the company’s position in the post‑genomic era, where high‑performance scientific instruments are in growing demand. The contracts also reinforce Bruker's strategy to expand its footprint in advanced scientific and medical‑imaging markets.
"These agreements are a testament to the confidence our customers have in Bruker’s superconducting technology and our ability to deliver on long‑term commitments," said Burkhard Prause, President and CEO of BEST. Prause added that the deals will help stabilize the division’s revenue base and support continued investment in helium‑free MRI and other high‑value applications.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.